EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aytu BioPharma's enterprise value is $12.16 Mil.
Aytu BioPharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $98.50 Mil. Therefore, Aytu BioPharma's EV-to-Revenue for today is 0.12.
The historical rank and industry rank for Aytu BioPharma's EV-to-Revenue or its related term are showing as below:
AYTU'
s EV-to-Revenue Range Over the Past 10 Years
Min: -2.48 Med: 0.28 Max: 4.66
Current: 0.12
During the past 13 years, the highest EV-to-Revenue of Aytu BioPharma was 4.66. The lowest was -2.48. And the median was 0.28.
AYTU's EV-to-Revenue is ranked better than 97.86% of 1026
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs AYTU: 0.12
As of today (2024-04-23), Aytu BioPharma's stock price is $2.715.
Aytu BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $21.85. Therefore, Aytu BioPharma's PS Ratio for today is 0.12.
Aytu BioPharma EV-to-Revenue Historical Data
The historical data trend for Aytu BioPharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma EV-to-Revenue Distribution
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's EV-to-Revenue falls into.
Aytu BioPharma's current Enterprise Value is $12.16 Mil.
Aytu BioPharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $98.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma's share price for today is $2.715.
Aytu BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.85.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Aytu BioPharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aytu BioPharma (Aytu BioPharma) Business Description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AYTU has been successfully added to your 